HDACs and their inhibitors in immunology: Teaching anticancer drugs new tricks

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 3-5

  Fairlie, David P ^a   Sweet, Matthew J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRICHOSTATIN A; VORINOSTAT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; AUTOPHAGY; CANCER IMMUNOLOGY; CELL CYCLE ARREST; CELL PROLIFERATION; COMPETITIVE INHIBITION; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DEACETYLATION; DRUG EFFICACY; EDITORIAL; ENZYME ACTIVITY; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFLAMMATION; MALARIA; MOLECULAR INTERACTION; NONHUMAN; PROTEIN METHYLATION; PROTEIN PROCESSING; RNA SYNTHESIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; VIRUS REPLICATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; NEOPLASMS;

EID: 84855441963     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.105     Document Type: Editorial

References (35)

1. Allfrey VG, Littau VC, Mirsky AE. On the roleof of histones in regulation ribonucleic acid synthesis in the cell nucleus. Proc Natl Acad Sci USA 1963; 49: 414-421.
2. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 1964; 51: 786-794.
3. Gallwitz D. Acetylation of histones by a kinase from rat liver nucle. Biochem Biophys Res Commun 1968; 32: 117-121.
4. Nohara H, Takahashi T, Ogata K. Enzymatic acetylation of histones and some chemical characters of their acetyl groups. Biochim Biophys Acta 1968; 154: 529-539.
5. Inoue A, Fujimoto D. Enzymatic deacetylation of histone. Biochem Biophys Res Commun 1969; 36: 146-150.
6. Inoue A, Fujimoto D. Histone deacetylase from calf thymus. Biochim Biophys Acta 1970; 220: 307-316.
7. Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murinevirus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971; 68: 378-382.
8. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-5708. (Pubitemid 26191313)
9. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeasttranscriptional regulator Rpd3p. Science 1996; 272: 408-411. (Pubitemid 26138177)
10. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histonedeacetylase both in vivoand in vitrobytrichostatin A. JBiol Chem 1990; 265: 17174-17179.
11. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. Aclass of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-3007. (Pubitemid 28135844)
12. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90. (Pubitemid 46087907)
13. Shiels IA, Taylor SM, Fairlie DP. Cell phenotype as a target of drug therapy in chronic inflammatorydiseases. Med Hypotheses 2000;54: 193-197. (Pubitemid 30170961)
14. Pogo BG, Allfrey VG, Mirsky AE. RNA synthesis and histone acetylation during the course of gene activation in lymphocytes. Proc Natl Acad Sci USA 1966; 55: 805-812.
15. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9: 309-319.
16. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflamma-tory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000. (Pubitemid 34240574)
17. Choi JH, Nam KH, Kim J, Baek MW, Park JE, Park HYet al. Trichostatin A exacerbates atherosclerosis in lowdensity lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 2404-2409. (Pubitemid 41552662)
18. Roger T, Lugrin J, Le Roy D,Goy G, Mombelli M, Koessler Tet al. Histonedeacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117: 1205-1217.
19. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappa B suppression. J Exp Med 2006; 203: 7-13. (Pubitemid 43139638)
20. Suliman BA, Xu D, Williams BRG. HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol Cell Biol 2012; 90: 23-32.
21. Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 2012; 90: 55-65.
22. Zhang H, Xiao Y, Zhu Z, Li B, Greene MI. Immune regulation by histonedeacetylases: A focus on the alteration of FOXP3 activity. Immunol Cell Biol 2012; 90: 95-100.
23. Trüe O, Matthias P. Interplay between histone deacetylases and autophagy\-from cancer therapy to neurodegeneration. Immunol Cell Biol 2012; 90: 78-84.
24. Kong S, Mc Burney MW, Fang D. Sirtuin 1 in immune regulation and autoimmunity. Immunol Cell Biol 2012; 90: 6-13.
25. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85-94.
26. Leggatt GR, Gabrielli B. Histone deacetylase inhibitors in the generation of the anti-tumour immune response. Immunol Cell Biol2012; 90: 33-38.
27. Sweet MJ, Shakespear MR, Kamal NA, Fairlie DP. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol 2012; 90: 14-22.
28. Iyer A, Fairlie DP, Brown L. Lysine acetylation in obesity, diabetes and metabolic disease. Immunol Cell Biol 2012; 90: 39-46.
29. Andrews KT, Haque A, Jones MK. HDAC inhibitors in parasitic diseases. Immunol Cell Biol 2012; 90: 66-77.
30. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunol Cell Biol 2012; 90: 47-54.
31. Chang HM, Paulson M, Holko M, Rice CM, Williams BR, Marie I et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacety-lase activity. Proc Natl Acad Sci USA 2004; 101: 9578-9583. (Pubitemid 38869278)
32. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M et al. The histone deacetylase HDAC11 regulates theexpression of interleukin 10and immunetolerance. Nat Immunol 2009; 10: 92-100.
33. Wang L, Tao R, Hancock WW. Using histonedeacetylase inhibitorstoenhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol 2009; 87: 195-202.
34. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45. (Pubitemid 30038513)
35. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.